Sign in

    Alterity Therapeutics Ltd (ATHE)

    You might also like

    Alterity Therapeutics Limited (ATHE) is a biotechnology company specializing in the development of therapeutic drugs for neurodegenerative diseases, with a primary focus on Parkinsonian disorders and related movement disorders. The company is a development-stage enterprise, advancing its pharmaceutical products through early to mid-stage clinical trials. Alterity does not sell commercial products but generates revenue through government grants, licensing, research collaborations, and interest income.

    1. Research and Development in Neurodegenerative Diseases - Focuses on discovering and developing therapeutic drugs targeting Parkinsonian disorders, including Multiple System Atrophy (MSA), a rare and debilitating condition with no approved treatments.
      • ATH434 - Lead drug candidate in Phase 2 clinical trials for MSA, designed to address the underlying pathology of the disease.
      • PBT2 - Previously developed for Alzheimer’s and Huntington diseases, with completed Phase 1 and Phase 2 trials.
    2. Discovery Platform - Maintains a chemical library of over 1,000 validated compounds designed for oral bioavailability and blood-brain barrier penetration, targeting the interrelationship of metals and proteins in neurodegenerative diseases.
    3. Collaborative Research - Partners with leading scientists and institutions, conducting research at The University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute.
    NamePositionExternal RolesShort Bio

    Dr. David Stamler

    Executive

    Chief Executive Officer

    None

    Dr. Stamler has extensive experience in drug development, previously serving as CMO at Alterity and leading the development of ATH434 for neurodegenerative diseases.

    View Report →

    Mr. Phillip Hains

    Executive

    Chief Financial Officer and Company Secretary

    Operates within Acclime Australia (formerly The CFO Solution)

    Mr. Hains has over 30 years of experience in financial reporting and compliance, specializing in supporting public companies.

    Mr. Brian Meltzer

    Board

    Director

    Director of Australia-Israel Chamber of Commerce; Chairman of Independence Australia

    Mr. Meltzer has a background in investment banking and corporate advisory, with expertise in property transactions, venture capital, and syndications.

    Mr. Geoffrey Kempler

    Board

    Chairman of the Board

    Chair of Hexima Ltd; Member of Turner Institute Advisory Board at Monash University

    Founder of Alterity, Mr. Kempler has a background in psychology and investment, with significant contributions to the company's strategic direction.

    Mr. Lawrence Gozlan

    Board

    Director

    Chief Investment Officer at Scientia Capital; Director of Opthea Limited

    Mr. Gozlan is a life sciences investment specialist, leading Scientia Capital and holding directorships in several biotech companies.

    Mr. Peter Marks

    Board

    Director

    Chairman of Newburyport Partners; Director of Noxopharm Limited, Iris Metals Limited, and Evergreen Lithium Limited

    Mr. Marks has over 35 years of experience in corporate advisory and investment banking, focusing on life sciences and high-tech sectors.